Therapeutic options for infections caused by Acinetobacter baumannii
| Autor: | K.J. Towner |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
medicine.medical_specialty
biology medicine.drug_class business.industry Antibiotics Tigecycline Sulbactam biology.organism_classification Surgery Acinetobacter baumannii Clinical trial Infectious Diseases Pharmacotherapy medicine Colistin Pharmacology (medical) Intensive care medicine business medicine.drug Antibacterial agent |
| Zdroj: | Antibiotiques. 11:150-157 |
| ISSN: | 1294-5501 |
| DOI: | 10.1016/j.antib.2009.06.003 |
| Popis: | Summary Objectives To analyse difficulties in treating patients with Acinetobacter infections and to consider potential new therapeutic options. Current situation Multidrug-resistant strains of A. baumannii and its close relatives have emerged as a significant cause of nosocomial infection during the last two decades. Carbapenems would normally be the agents of choice for the treatment of severe infections caused by these organisms. However, the emergence and spread of carbapenem resistance means that therapy of infections caused by these organisms now frequently requires new therapeutic approaches. Use of unusual drugs The therapeutic options available for treating Acinetobacter infections are now extremely limited, or even non-existent, in certain centres. Unusual drugs are sometimes used, e.g., colistin or sulbactam, often in novel combinations, or drugs with which there is presently very little clinical experience (e.g., tigecycline). No large prospective controlled clinical trials for the treatment of A. baumannii infections with these drugs have been published to date. Conclusion Knowledge of the best therapeutic approaches is currently based only on in-vitro susceptibility data, small case series and retrospective analysis of observational studies. There is an urgent need for well-controlled clinical trials of existing and new therapies for the treatment of infections caused by A. baumannii . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|